TriangleNCT00743288 · OUTCOME
Duration of Response
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- months
- Interval / dispersion
- Full Range
- Time frame
- First evidence of PR or better (for overall response) and MR or better (for clinical benefit response) to start of disease progression or death
Analysis population: Only three patients had responses.
Groups in this outcome
Melphalan and Panobinostat Schedule B
B1: 10mg/daily LBH589 on days 1, 3 and 5 of weeks 1-4 and 0.05mg/kg melphalan on days 1, 3 and 5 of week 1. B2: 20mg/daily LBH589 on days 1, 3 and 5 of weeks 1-4 and 0.05mg/kg melphalan on days 1, 3 and 5 of week 1.
| Group | Source count |
|---|---|
| Melphalan and Panobinostat Schedule B | 3 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Melphalan and Panobinostat Schedule B | 8.1 | Not reported | 0 | 17.2 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 0
- upper Limit
- 17.2
- value
- 8.1
- denoms
- counts
- group Id
- OG000
- value
- 3
- units
- Participants
- dispersion Type
- Full Range
- groups
- description
- B1: 10mg/daily LBH589 on days 1, 3 and 5 of weeks 1-4 and 0.05mg/kg melphalan on days 1, 3 and 5 of week 1. B2: 20mg/daily LBH589 on days 1, 3 and 5 of weeks 1-4 and 0.05mg/kg melphalan on days 1, 3 and 5 of week 1.
- id
- OG000
- title
- Melphalan and Panobinostat Schedule B
- param Type
- MEDIAN
- population Description
- Only three patients had responses.
- reporting Status
- POSTED
- time Frame
- First evidence of PR or better (for overall response) and MR or better (for clinical benefit response) to start of disease progression or death
- title
- Duration of Response
- type
- SECONDARY
- unit Of Measure
- months
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice